Inflammatory breast cancer is a specific lesion in the pathogenesis of breast cancer that can occur in all types of breast cancer without pathologic tissue type specificity. Pathological histological studies suggest that this secondary inflammatory lesion of breast cancer is due to the infiltration of cancer cells into the subdermal lymphatic vessels, triggering lymphatic vessel obstruction and secondary inflammation. Inflammatory breast cancer is mainly manifested by invasion of lymphatic tracts, has a high chance of metastasis, and is the worst prognosis among locally advanced breast cancers. The incidence of inflammatory breast cancer accounts for 1% to 10% of all breast cancers, and in China, it accounts for 0.9% of breast cancers. Inflammatory breast cancer has a rapid onset and most of the patients present with inflammatory symptoms such as redness, swelling, heat, pain and pressure on the breast skin. Signs of inflammatory breast cancer include diffuse or limited skin sclerosis, thickening, uneven surface, edema resembling orange peel, and satellite nodules. The skin is initially pink, but soon becomes petechial purplish-red, with a tan-like change. The breasts are rapidly enlarging, the skin temperature is increased, and the nipples are dry, cracked, crusted and invaginated to touch. Treatment The incidence of metastasis in inflammatory breast cancer is as high as 30% to 40%, so the prognosis of patients with this type of breast cancer is not good. The 5-year survival rate for surgery alone is less than 10%, with a median survival of 12 to 32 months. The median survival for radiation therapy alone or radiation therapy plus surgery is only 4 to 29 months. The median survival of hormone therapy alone was not significantly longer. Most patients die from distant metastases within a few months of diagnosis, regardless of radiotherapy or surgery. For this reason, medical experts have designed comprehensive treatment protocols: induction chemotherapy – local treatment (radiotherapy or surgery) – systemic chemotherapy. Recent studies have shown the effectiveness of chemotherapy plus high-dose radiation therapy for inflammatory breast cancer, increasing the 3-year survival rate to 30%-50%. The 5-year tumor-free survival rate for chemotherapy plus surgical treatment plus radiotherapy is 22% to 48%, with an average survival of 25 to 56 months or more. With the progress of medical science research, the clinical application of autologous bone marrow transplantation technology has led to mega-dose chemotherapy followed by autologous bone marrow transplantation regimen into the treatment of inflammatory breast cancer, which has greatly improved the survival rate.